Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000541228 | SCV000642561 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2024-01-11 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 34897 of the TTN protein (p.Ser34897Leu). This variant is present in population databases (rs373446383, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with TTN-related conditions. ClinVar contains an entry for this variant (Variation ID: 466732). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. This variant is located in the M band of TTN (PMID: 25589632). Non-truncating variants in this region may be relevant for neuromuscular disorders, but have not been definitively shown to cause cardiomyopathy (PMID: 23975875). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Eurofins Ntd Llc |
RCV000593937 | SCV000701147 | uncertain significance | not provided | 2017-05-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002404464 | SCV002674771 | uncertain significance | Cardiovascular phenotype | 2018-09-27 | criteria provided, single submitter | clinical testing | The p.S25832L variant (also known as c.77495C>T), located in coding exon 185 of the TTN gene, results from a C to T substitution at nucleotide position 77495. The serine at codon 25832 is replaced by leucine, an amino acid with dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000593937 | SCV003822840 | uncertain significance | not provided | 2019-07-08 | criteria provided, single submitter | clinical testing |